Abstract
On October 24, 2019, a marketing authorization valid through the European Union (EU) was issued for gilteritinib monotherapy for adult patients who have relapsed or refractory acute myeloid leukemia (AML) with an Fms-like tyrosine kinase 3 (FLT3) mutation. Gilteritinib inhibits FLT3 receptor signaling and proliferation in cells exogenously expressing FLT3 including FLT3 internal tandem duplication (ITD), FLT3 D835Y, and FLT3 ITD D835Y, and it induced apoptosis in leukemic cells expressing FLT3 ITD. The recommended starting dose of gilteritinib is 120 mg (three 40 mg tablets) once daily. Gilteritinib was evaluated in one, phase III, open-label, multicenter, randomized study of gilteritinib (n = 247, gilteritinib arm) versus salvage chemotherapy (n = 124, salvage chemotherapy arm) in patients with relapsed or refractory AML with FLT3 mutation. Overall survival (OS) was statistically significantly different between the two groups with a median OS of 9.3 months in the gilteritinib arm compared with 5.6 months for salvage chemotherapy (hazard ratio, 0.637; 95% confidence interval, 0.490-0.830; p = .0004 one-sided log-rank test). The most common adverse reactions with gilteritinib treatment were blood creatine phosphokinase increase,...Continue Reading
References
May 22, 2003·Genes, Chromosomes & Cancer·Christine SteudelChristian Thiede
Dec 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards
Aug 4, 2004·Leukemia Research·Jens TiesmeierWalter Verbeek
Jun 17, 2005·Leukemia·M YanadaT Naoe
Oct 25, 2007·Blood·Rosemary E GaleUNKNOWN Medical Research Council Adult Leukaemia Working Party
Dec 8, 2007·Cancer Causes & Control : CCC·Jennifer F Yamamoto, Marc T Goodman
Mar 16, 2012·The New England Journal of Medicine·Jay P PatelRoss L Levine
Jul 10, 2012·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·O VisserUNKNOWN RARECARE Working Group
Jan 6, 2017·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Jun 25, 2017·The Lancet Oncology·Alexander E PerlMark Levis
Jul 25, 2018·Cancer Science·Kensuke UsukiTomoki Naoe
Oct 23, 2018·Medicina·Natasa MaksimovicTatjana Pekmezovic
Citations
Aug 11, 2020·Expert Opinion on Pharmacotherapy·Alejandro Garcia-Horton, Karen Wl Yee
Dec 17, 2020·Life·Valentina GiudiceCarmine Selleri
Apr 28, 2021·European Journal of Medicinal Chemistry·Xiaoxia LiangBo Jing
May 1, 2021·Journal of Clinical Medicine·Matteo PicciniGiacomo Gianfaldoni
Jun 7, 2021·Bioorganic Chemistry·Xiaoxia LiangBo Jing
Jul 22, 2021·Journal of Medicinal Chemistry·Neetu DayalHerman O Sintim